Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.

Summary, in English

Bone marrow-derived mesenchymal stromal cells (MSCs) target glioma extensions and micro-satellites efficiently when implanted intratumorally. Here, we report that intratumoral implantation of MSCs and peripheral immunotherapy with interferon-gamma (IFNγ) producing tumor cells improve the survival of glioma-bearing rats (54% cure rate) compared to MSC alone (0% cure rate) or immunotherapy alone (21% cure rate) by enforcing an intratumoral CD8(+) T cell response. Further analysis revealed that the MSCs up-regulate MHC classes I and II in response to IFNγ treatment in vitro and secrete low amounts of immunosuppressive molecules prostaglandin E2 and interleukin-10.

• Author: Salina Ströjby; Sofia Eberstål; Andreas Svensson; Sara Fritzell; Daniel Bexell; Peter Siesjö; Anna Darabi; Johan Bengzon
• Department/s: Neurosurgery; Division of Translational Cancer Research; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation; StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
• Publishing year: 2014
• Language: English
• Pages: 240-243
• Publication/Series: Journal of Neuroimmunology
• Volume: 274
• Issue: 1-2
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25086876?dopt=Abstract; http://dx.doi.org/10.1016/j.jneuroim.2014.07.014
• Document type: Journal article
• Publisher: Elsevier
• Topic: Neurology
• Status: Published
• ISBN/ISSN/Other: ISSN: 1872-8421